Study Reveals Significant Extension in Progression-Free and Overall Survival Rates
In an international phase 3 trial, radioligand therapy using 177Lu-PSMA-617 demonstrated substantial benefits in treating advanced PSMA-positive metastatic castration-resistant prostate cancer. The therapy not only extended progression-free survival but also improved overall survival rates, offering a new avenue for treatment.
HCN Medical Memo
This study underscores the potential of 177Lu-PSMA-617 as a viable treatment option. Although adverse events were higher, the significant extension in both progression-free and overall survival rates cannot be overlooked. This therapy could be a game-changer in improving patient outcomes.
- International, open-label, phase 3 trial
- Participants: 831 of 1179 screened patients with metastatic castration-resistant prostate cancer
- Treatment: 177Lu-PSMA-617 (7.4 GBq every 6 weeks for 4-6 cycles) plus standard care or standard care alone
- Primary Endpoints: Imaging-based progression-free survival and overall survival
- Secondary Endpoints: Objective response, disease control, and time to symptomatic skeletal events
- Adverse events monitored up to 30 days after the last dose
Metastatic castration-resistant prostate cancer remains fatal in most cases despite recent advances in treatment.
- Median imaging-based progression-free survival: 8.7 months with 177Lu-PSMA-617 vs. 3.4 months with standard care (P<0.001)
- Median overall survival: 15.3 months with 177Lu-PSMA-617 vs. 11.3 months with standard care (P<0.001)
- All key secondary endpoints significantly favored 177Lu-PSMA-617
- Incidence of grade 3 or above adverse events was higher in the 177Lu-PSMA-617 group (52.7% vs. 38.0%), but quality of life remained stable
More on Prostate Cancer